Genetic regulation of β-ureidopropionase and its possible implication in altered uracil catabolism

Pharmacogenetics and Genomics

Volumn 18, Issue 1, 2008, Pages 25-35

  Thomas, Holly R ^a   Ezzeldin, Hany H ^a,b   Guarcello, Vincenzo ^a   Mattison, Lori K ^a,b   Fridley, Brooke L ^c   Diasio, Robert B ^a,b,c,d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MAYO CLINIC   (United States)

^d NONE   (United States)

Author keywords

ureidopropionase; 13C uracil breath test; Denaturing high performance liquid chromatography; Dihydropyrimidinase; Uracil catabolism

Indexed keywords

BETA UREIDOPROPIONASE; DIHYDROPYRIMIDINE DEHYDROGENASE; UNCLASSIFIED DRUG; URACIL;

ADULT; ARTICLE; CATABOLISM; CELL LINE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENETIC REGULATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UREA BREATH TEST;

AMIDOHYDROLASES; BETA-GALACTOSIDASE; BREATH TESTS; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIHYDROURACIL DEHYDROGENASE (NADP); GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MUTAGENESIS, SITE-DIRECTED; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; URACIL;

EID: 38549153294     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3282f2f134     Document Type: Article

References (37)

1. Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 2001; 41:151-157.
2. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolism in plasma, urine, and bile. Cancer Res 1987; 47:2203-2206.
3. Sakamoto T, Sakata S, Matsuda K, Horikawa Y, Tamaki N. Expression and properties of human liver beta-ureidopropionase. J Nutr Sci Vitaminol 2001; 47:132-138.
4. Van Kuilenburg A, van Lenthe H, van Gennip A. Activity of pyrimidine degradation enzymes in normal tissues. Nucleosides Nucleotides Nucleic Acids 2006; 25:1211-1214.
5. Sumi S, Imaeda M, Kidouchi K, Ohba S, Hamajima N, Kodama K, et al. Population and family studies of dihydropyrimidinuria: prevalence, inheritance mode, and risk of fluorouracil toxicity. Am J Med Genet 1998; 78:336-340.
6. Hamajima N, Kouwaki M, Vreken P, Matsuda K, Sumi S, Imaeda M, et al. Dihydropyrimidinase deficiency: structural organization, chromosomal localization, and mutation analysis of the human dihydropyrimidinase gene. Am J Hum Genet 1998; 63:717-726.
7. Van Kuilenburg AB, Meinsma R, Beke E, Assmann B, Ribes A, Lorente I, et al. Beta-ureidopropionase deficiency: an inborn error of pyrimidine degradation associated with neurological abnormalities. Hum Mol Genet 2004; 13:2793-2801.
8. Van Kuilenburg AB, Van Lenthe H, Assmann B, Gohlich-Ratmann G, Hoffmann GF, Brautigam C, et al. Detection of beta-ureidopropionase deficiency with HPLC-electrospray tandem mass spectrometry and confirmation of the defect at the enzyme level. J Inherit Metab Dis 2001; 24:725-732.
9. Hartmann S, Okun JG, Schmidt C, Langhans CD, Garbade SF, Burgard P, et al. Comprehensive detection of disorders of purine and pyrimidine metabolism by HPLC with electrospray ionization tandem mass spectrometry. Clin Chem 2006; 52:1127-1137.
10. Ohse M, Matsuo M, Ishida A, Kuhara T. Screening and diagnosis of beta-ureidopropionase deficiency by gas chromatographic/mass spectrometric analysis of urine. J Mass Spectrom 2002; 37:954-962.
11. Moolenaar SH, Gohlich-Ratmann G, Engelke U, Spraul M, Humpfer E, Dvortsak P, et al. Beta-ureidopropionase deficiency: a novel inborn error of metabolism discovered using NMR spectroscopy on urine. Magn Reson Med 2001; 46:1014-1017.
12. Johnson MR, Hageboutros A, Wang K, High L, Smith J, Diasio RB. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999; 5:2006-2011.
13. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 2002; 8:768-774.
14. Van Kuilenburg AB, Meinsma R, Zonnenberg BA, Zoetekouw L, Baas F, Matsuda K, et al. Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res 2003; 9:4363-4367.
15. 13C-uracil breath test. Clin Cancer Res 2004; 10:2652-2658.
16. 3C]dihydrouracil. Clin Cancer Res 2006; 12:549-555.
17. Johnson MR, Yan J, Shao L, Albin N, Diasio RB. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatograph B Biomed Sci Appl 1997; 696:183-191.
18. 1H NMR Spectroscopy of body fluids: inborn errors of purine and pyrimidine metabolism. Clin Chem 1999; 45:539-548.
19. Kuhara T, Ohdoi C, Ohse M, van Kuilenburg AB, van Gennip AH, Sumi S, et al. Rapid gas chromatographic-mass spectrometric diagnosis of dihydropyrimidine dehydrogenase deficiency and dihydropyrimidinase deficiency. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 792:107-115.
20. Thomas H, Ezzeldin H, Guarcello V, Mattison L, Fridley B, Diasio RB. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics 2007; 17:973-987.
21. Vreken P, van Kuilenburg AB, Hamajima N, Meinsma R, van Lenthe H, Gohlich-Ratmann G, et al. cDNA cloning, genomic structure and chromosomal localization of the human BUP-1 gene encoding beta-ureidopropionase. Biochim Biophys Acta 1999; 1447:251-257.
22. Van Gennip AH, Abeling NG, Vreken P, van Kuilenburg AB. Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects. J Inherit Metab Dis 1997; 20:203-213.
23. Van Kuilenburg AB, van Lenthe H, Rattmann GG, Assmann B, Hoffmann GF, Brautigam C, et al. Confirmation of the enzyme defect in the first case of beta-ureidopropionase deficiency. Adv Exp Med Biol 2000; 486:243-246.
24. Assmann B, van Kuilenburg A, Distelmaier F, Abeling NG, Rosenbaum T, Schaper J, et al. Beta-ureidopropionase deficiency presenting with febrile status epilepticus. Epilepsia 2006; 47:215-217.
25. Van Gennip AH, van Lenthe H, Abeling NG, Scholten EG, van Kuilenburg AB. Inhibition of beta-ureidopropionase by propionate may contribute to the neurological complications in patients with propionic acidaemia. J Inherit Metab Dis 1997; 20:379-382.
26. Kolker S, Okun JG, Horster F, Assmann B, Ahlemeyer B, Kohlmuller D, et al. 3-Ureidopropionate contributes to the neuropathology of 3-ureidopropionase deficiency and severe propionic aciduria: a hypothesis. J Neurosci Res 2001; 66:666-673.
27. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993; 53:5433-5438.
28. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, editors. Bioinformatics methods and protocols: methods in molecular biology. Totowa, New Jersey: Humana Press; 2000. pp. 365-386.
29. Ezzeldin H, Okamoto Y, Johnson MR, Diasio RB. A high throughput denaturing high performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal Biochem 2002; 306:63-73.
30. Ezzeldin H, Johnson MR, Okamoto Y, Diasio RB. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin Cancer Res 2003; 9:3021-3028.
31. Qui P, Shandilya H, D'Alessio J, O'Connor K, Durocher J, Gerard G. Mutation detection using Surveyor nuclease. Biotechniques 2004; 36: 702-707.
32. 14C 5, 6-dihydrouracil. Anal Biochem 1999; 272: 250-253.
33. Ng PC, Henikoff S. Accounting for human polymorphisms predicted to affect protein function. Genome Res 2002; 12:436-446.
34. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
35. Agresti A. Categorical data analysis. 2nd ed. New Jersey: Wiley Press; 2002.
36. Dempster AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via the EM algorithm. J R Stat Soc Ser B Meth 1977; 39:1-38.
37. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995; 12:921-927.